FDA approves Roche's Gazyva/Gazyvaro for primary membranous nephropathy in adults
The FDA approved Roche's Gazyva/Gazyvaro for adults with primary membranous nephropathy; in the Phase III MAJESTY trial, 36.1% achieved complete remission at two years, versus 5.7% with tacrolimus.
1. FDA approval
The FDA approved Gazyva/Gazyvaro for primary membranous nephropathy in adults. In the Phase III MAJESTY trial, the treatment achieved a 36.1% complete remission rate at two years, compared with 5.7% for tacrolimus.





